Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (121-130 of 301) with videos related to

Pageof 31
Sort By:
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 TrialsJean-Luc Harousseau, Herve Avet-Loiseau, Michel Attal, et al.
Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.
Cancer Medicine|February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trialsPhilippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myelomaGuillemette Fouquet, Stéphanie Guidez, Charles Herbaux, et al.
Genome Medicine|August 10, 2021
The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variabilityJennifer Derrien, Catherine Guérin-Charbonnel, Victor Gaborit, et al.
Haematologica|February 17, 2022
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 studyCyrille Touzeau, Aurore Perrot, Murielle Roussel, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Pageof 31

Showing results (121-130 of 301) with videos related to

Sort By:
Pageof 31
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 TrialsJean-Luc Harousseau, Herve Avet-Loiseau, Michel Attal, et al.
Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.
Cancer Medicine|February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trialsPhilippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2020
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple MyelomaMax S Topp, Johannes Duell, Gerhard Zugmaier, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myelomaGuillemette Fouquet, Stéphanie Guidez, Charles Herbaux, et al.
Genome Medicine|August 10, 2021
The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variabilityJennifer Derrien, Catherine Guérin-Charbonnel, Victor Gaborit, et al.
Haematologica|February 17, 2022
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 studyCyrille Touzeau, Aurore Perrot, Murielle Roussel, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Pageof 31